CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.

Harbeck, Nadia; Bartlett, Meaghan; Spurden, Dean; Hooper, Becky; Zhan, Lin; Rosta, Emily; Cameron, Chris; Mitra, Debanjali; Zhou, Anna

Harbeck, Nadia; Bartlett, Meaghan; Spurden, Dean; Hooper, Becky; Zhan, Lin; Rosta, Emily; Cameron, Chris; Mitra, Debanjali; Zhou, Anna.

Affiliation

Harbeck N; Breast Center, Department of Gynecology & Obstetrics & Comprehensive Cancer Center, LMU University Hospital, Munich, 81377, Germany.
Bartlett M; CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada.
Spurden D; Pfizer, Inc., NY 10017, USA.
Hooper B; CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada.
Zhan L; Pfizer, Inc., NY 10017, USA.
Rosta E; CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada.
Cameron C; CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada.
Mitra D; Pfizer, Inc., NY 10017, USA.
Zhou A; CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada.

Future Oncol ; 17(16): 2107-2122, 2021 Jun.

Article in En | MEDLINE | ID: mdl-33663223

Subject(s)
Key words

CDK4/6i; biological therapy; breast; metastasis; real-world evidence; systematic literature review

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Progesterone / Receptor, ErbB-2 / Estrogen Receptor alpha / Cyclin-Dependent Kinase 4 / Cyclin-Dependent Kinase 6 Type of study: Systematic_reviews Limits: Female / Humans Language: En Journal: Future Oncol Year: 2021 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google